Pfizer Dopamine HCl injection recalled for lack of sterility assurance
Pfizer has recalled one lot of Dopamine HCl injection (40 mg/mL) distributed nationwide due to a lack of assurance of sterility. The affected lot is NL5230, with an expiration date of October 2027. This is a precautionary measure to ensure patient safety.
From the FDA notice · Read the official notice ↗
What to do
- Check your facility's dopamine stock for lot number NL5230.
- Do not use vials from this lot.
- Contact Pfizer or your supplier for return or replacement instructions.
- Report any adverse events to the FDA MedWatch program.
Is yours affected?
Compare your label or packaging with the recalled product.
- Product
- Dopamine HCl Inj., USP, 200 mg/5 mL (40 mg/mL), 5 mL Single-dose, 25 vials per tray, Rx only, Distributed by Hospira, Inc., Lake Forest, IL 60045 USA, Vial NDC 0409-5820-11, Carton NDC 0409-5820-01.
- Sold in
- Nationwide
- Made for
- All ages (0 months and older)
Details
- Units affected
- N/A
- Illnesses reported
- None reported
- Manufactured in
- 66 Hudson Blvd, N/A, Manhattan, NY, United States
- Classification
- Class II
- Recall number
- D-0853-2026
In the FDA's words
- Description
- Dopamine HCl Inj., USP, 200 mg/5 mL (40 mg/mL), 5 mL Single-dose, 25 vials per tray, Rx only, Distributed by Hospira, Inc., Lake Forest, IL 60045 USA, Vial NDC 0409-5820-11, Carton NDC 0409-5820-01. Lack of Assurance of Sterility Lot # NL5230, Exp Date:10/2027 Distribution: US Nationwide. Affected quantity: N/A
- Hazard
- Lack of Assurance of Sterility
More from Pfizer
- Pfizer Levoxyl 175 mcg tablets recalled for subpotent drug content
ModerateFDAOct 16, 2026